Tirbanibulin for Pediatric Warts
Condition(s) studied
Investigational drug(s) / intervention(s)
Tirbanibulin ointment 1%: Topical application
Study summary
Warts are common, benign skin lesions caused by the human papillomavirus (HPV). Treatment is challenging, particularly in the pediatric population, where standard modalities such as cryotherapy and intralesional immunotherapy are poorly tolerated. Existing topical treatments, such as imiquimod and 5-fluorouracil, have low efficacy and require prolonged use. Case reports suggest tirbanibulin ointment may provide an effective and well-tolerated alternative for pediatric warts. This study will evaluate the efficacy and safety of tirbanibulin ointment in treating pediatric hand warts.
Eligibility
Primary outcome measure(s)
- Resolution — 2 months aftre completion of 4 or less treatment cycles
Ful resolution of treated lesions
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| The Skin Center Dermatology Group | New City | New York | Recruiting |
More The Skin Center Dermatology Group trials in the USA
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06791525 on ClinicalTrials.gov ↗ ← All trials in the USA